glp 1 and thyroid cancer New evidence continues to shape what we know about GLP-1 medications. A June 2026 real-world study followed nearly 400,000 adults starting GLP-1 receptor agonists. Key findings: ⚡️ No increased risk glp-1 drugs and thyroid cancer

BSO did not increase lipid ROS or death in resting B-cells, but strongly induced lipid ROS and 7-AAD uptake in cells stimulated for 2 days by CD40L+IL-4

Risk of fracture A pooled analysis of data from several prospective cohort studies, including the EPIC-Elderly Greece (9,534 participants), EPIC-Elderly Sweden (3,276 participants), Cohort of Swedish Men (COSM

Coverage is based on the type of insurance you have and your individual policy

Body composition changes required 3 to 6 months of continuous use in reported trials

It is also essential to elucidate how the hepatic microenvironment influences the functional state of immune cells through metabolic reprogramming